
BLCO Stock Forecast & Price Target
BLCO Analyst Ratings
Bulls say
Bausch & Lomb has raised its 2025 revenue guidance to between $5,050 million and $5,150 million, indicating anticipated constant currency growth of 5-7%, with adjusted EBITDA projected to reach between $860 million and $910 million. The company has reported a robust 6% revenue growth on a constant currency basis, positively influenced by foreign exchange gains and significant growth in prescription sales for MIEBO and XIIDRA. Additionally, the regained momentum in premium intraocular lenses highlights Bausch & Lomb's competitive strengths in key market segments, reinforcing a favorable outlook for sustained financial performance.
Bears say
Bausch & Lomb's stock outlook is negatively impacted by several fundamental challenges including pricing pressure on key products like XIIDRA, which could constrain revenue growth and profitability. The company's limited product pipeline and high leverage, stemming from the acquisition of Xiidra, coupled with macroeconomic uncertainties surrounding consumer spending and elective procedures, pose additional risks to its financial stability. Furthermore, ongoing concerns regarding its separation from parent company Bausch Health and potential market volatility from private equity rumors further contribute to the negative sentiment surrounding Bausch & Lomb's stock performance.
This aggregate rating is based on analysts' research of Bausch + Lomb Corp and is not a guaranteed prediction by Public.com or investment advice.
BLCO Analyst Forecast & Price Prediction
Start investing in BLCO
Order type
Buy in
Order amount
Est. shares
0 shares